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Abstract
Background—Comparative effectiveness research (CER) can efficiently and rapidly generate
new scientific evidence and address knowledge gaps, reduce clinical uncertainty, and guide health
care choices. Much of the potential in CER is driven by the application of novel methods to
analyze existing data. Despite its potential, several challenges must be identified and overcome so
that CER may be improved, accelerated, and expeditiously implemented into the broad spectrum
of cancer care and clinical practice.
Methods—To identify and characterize the challenges to cancer CER, we reviewed the literature
and conducted semi-structured interviews with 41 cancer CER researchers at the Agency for
Healthcare Research and Quality (AHRQ)'s Developing Evidence to Inform Decisions about
Effectiveness (DEcIDE) Cancer CER Consortium.
Results—A number of datasets for cancer CER were identified and differentiated into an
ontology of eight categories, and characterized in terms of strengths, weaknesses, and utility.
Several themes emerged during development of this ontology and discussions with CER
researchers. Dominant among them was accelerating cancer CER and promoting the acceptance of
findings, which will necessitate transcending disciplinary silos to incorporate diverse perspectives
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and expertise. Multidisciplinary collaboration is required including those with expertise in non-
experimental data, outcomes research, clinical trials, epidemiology, generalist and specialty
medicine, survivorship, informatics, data, and methods, among others.
Conclusions—Recommendations highlight the systematic, collaborative identification of
critical measures; application of more rigorous study design and sampling methods; policy-level
resolution of issues in data ownership, governance, access, and cost; and development and
application of consistent standards for data security, privacy, and confidentiality.
INTRODUCTION
Rapid advances in cancer care continues through an accelerated pace of scientific discovery
and technology development. Timely integration of developments into clinical practice is
increasingly challenging, and it is imperative for more immediate, generalizable, and
evidence-based information. Randomized controlled trials (RCTs) remain the gold standard
for developing such information; however, this research design is not always feasible,
practical, or sufficiently timely. Additionally, RCT designs limit generalizability of findings
to heterogeneous patient populations or specific subgroups seen in clinical practice. 1-7
Cancer comparative effectiveness research (CER) holds great promise for meeting many
shortcomings of RCTs. Though CER takes many forms, for this discussion, we focus on the
Institute of Medicine's (IOM) definition of CER:
Comparative effectiveness research is the generation and synthesis of evidence that
compares the benefits and harms of alternative methods to prevent, diagnose, treat,
and monitor a clinical condition or to improve the delivery of care. The purpose of
CER is to assist consumers, clinicians, purchasers, and policy makers to make
informed decisions that will improve health care at both the individual and
population levels.6, 8
The foundation of CER is understanding effectiveness in the context of large, heterogeneous
populations. Propitiously, large population-based data are becoming increasingly available
through advances in information technology and research methods in the form of secondary
data collected for non-research purposes. By increasing our understanding of these data,
CER stands to benefit immeasurably by these ever-growing repositories.
For cancer CER, these data originate from many different sources including electronic
health records, registries, administrative data, observational studies, clinical trials, and
others. Not all existing or secondary data are adequate, and each data source comes with its
own unique challenges. Because secondary data originate from many different sources, they
may be missing critical variables or have significant and systematic differences how
variables are measured. . These differences impede the ability to confidently characterize
important care processes and outcomes across data. An additional challenge is the lack of
randomization, which makes controlling for relevant confounders critical. As a result, cancer
care stakeholders are frequently uncomfortable acting on CER findings generated from these
data sources.
A better understanding of data is necessary to improve data collection and methods
development, to overcome the challenges facing cancer CER. To further this understanding,
and help guide federal data and research partners, we reviewed the literature and met with
over 40 cancer outcomes researchers and clinicians. Our goals were to: 1) develop a
conceptual model for examining observational data in cancer CER; 2) characterize the
strengths and limitations of current cancer CER data resources; 3) identify barriers in the
conduct of cancer CER; and 4) formulate recommendations and guiding principles. While
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our focus was on secondary, observational data (i.e., non-randomized, retrospective), the
findings we present are also applicable to any prospective data collection.
METHODS
Data collection
Literature was reviewed regarding current cancer care, cancer research data, and cancer
comparative effectiveness research. This information helped inform the development of a
conceptual model of data needs for cancer CER,9 and frame discussions with a convenience
sample of cancer outcomes researchers associated with the Can-DEcIDE Consortium.a
Participants were from multiple disciplines and included clinicians, clinical trials experts,
epidemiologists, pharmacoepidemiologists, health services researchers, biostatisticians,
clinical data managers, state public health workers, and informaticians. The majority of
participants relied on federal or academic funding; individuals who relied on funding from
industry or non-government third party payers were not targeted in the initial sampling
frame. Applying snowball sampling, participants were asked to identify other researchers
that may provide additional insight, and together comprised the study sample of 41
discussants.
Discussions were conducted individually and tailored according to each researcher's area of
expertise. Guided by findings in the literature, discussions centered on the following: 1)
identification of specific datasets for cancer CER; 2) utility of measures 3) data access or
logistical challenges; 4) population/target and sampling; 5) data linking capabilities; 6)
longitudinal follow-up in datasets; 7) temporality of data/measures; 8) data completeness; 9)
data standardization, formatting, and documentation; and 10) data processing and required
expertise.
Study Team Review and Development of Recommendations
The primary study team comprised an epidemiologist, pharmacoepidemiologist,
biostatistician, health services researcher, and three cancer-focused physician researchers, all
of whom conduct federally-funded patient centered cancer outcomes research. The study
team met multiple times to summarize key informant interviews, integrate it with
information from the literature, and organize the findings into categories and themes. These
meetings were audiotaped to ensure capture of the entire discussion. Recommendations were
collaboratively developed by the study team and reflect broad themes observed in the
literature, results from the interviews, and specific issues or examples specified by multiple
participants. Draft findings and recommendations were subsequently reviewed by select
participants and other outcomes researchers to assure their accuracy and face validity.
Lastly, the entire manuscript was reviewed by external experts participating in the AHRQ
DEcIDE network.
RESULTS
Data Sources for Cancer CER
We identified 46 relevant datasets from our study sample of cancer outcomes researchers.
Participants themselves expressed different opinions with regard to which data were
important, adequate, or weak for cancer CER. This variability highlighted the lack of
aAssociated with UNC Can-DEcIDE from: the University of North Carolina at Chapel Hill, Duke University, the Centers for Disease
Control and Prevention, the Brigham and Women's Hospital, the University of Virginia, the Epidemiologic Research and Information
Center at the Durham Veteran's Affairs Medical Center, the NC Central Cancer Registry, Blue Cross and Blue Shield of NC, Agency
for Healthcare Research and Quality, and the National Cancer Institute.
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standardized nomenclature associated with these data. Therefore, our first priority was to
identify patterns with which we could organize existing datasets and broad themes. 10-29
Inspection of the datasets and their purposes revealed that a consistent nomenclature was
needed before they could be easily organized to support CER. In response, an ontology was
developed which divided the data into eight categories, including six “existing or fixed data”
categories and two “hybrid” categories (Table 1).
Definitive empirical definitions for each category were difficult since they are not mutually
exclusive. This was complicated by the fact that participants from different clinical and
methodological specialties prioritized different characteristics of the datasets. Despite this,
the study team reached consensus and unanimously agreed on the final ontology, which had
face validity to internal and external reviewers, and provides useful classification and
characterization of the datasets. Table 2 presents an illustrative sampling of what were
perceived to be key datasets, assigned categories, and a summary of their strengths,
limitations, and applicability for cancer CER, as-informed by the discussants and study
team.
Barriers to the Conduct of Cancer CER
Several consistent themes emerged through the discussions and analysis: (1) There is a need
for systematically identified, standardized measures to fill gaps and enhance data linkage
and transferability. (2) Improvements in study design and population sampling are critical
for CER studies to be meaningful. (3) Substantial issues exist regarding data ownership,
access, governance, and cost. (4) Data security, privacy, and confidentiality remain
paramount. (5) Broad multidisciplinary representation is needed to effectively address these
CER data needs. These themes were consistent throughout the analysis and resonated with
key informants and the study team.
DISCUSSION
We have developed a novel framework for organizing and characterizing cancer CER data
together with relevant research needs. Based on the literature and key informant interviews,
we propose a practical ontology regarding data resources and availability. The structure of
this ontology was defined through a retrospective lens, by asking participants to nominate
secondary sources of data that could be immediately leveraged or developed.
The retrospective lens provides a starting point from which a rational ontology can be
developed. It allows us to define and characterize available data resources ready for cancer
CER. And lastly, it provides a characterized delineation point, for transition from
retrospective data models to prospective CER data models. Moving forward, we anticipate a
transition to more frequent prospective and real-time data collection activities (electronic
health records, continuously aggregating registries, rapid learning data systems). The
ontology proposed from our study provides a foundational nomenclature from which to
build future data resources. Increasingly clear throughout the fields of science and
engineering is the need to organize and systematically structure data so that information can
be maximally extracted to assist in prescribing the right treatment at the right time for a
specific patient. Moreover, we need agreement and collaboration from the respective
stakeholders of the multiple diverse systems for collecting data. This study highlights these
realities and helps to point a practical way forward.
Our approach includes several limitations. Development of this ontology was challenged by
a lack of mutual exclusivity among datasets and the diverse perspectives of participants. Our
federally-funded study team was focused on describing datasets and CER opportunities with
a government perspective. Our sampling was purposeful but not exhaustive; additional
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cancer CER datasets have likely been missed, and the relative impact on the ontology is not
clear.
Despite these challenges, this work provides a practical ontology that is adaptive and can be
upgraded over time. It provides a template for understanding the strengths and limitations of
current CER data resources, and formulating recommendations and guiding principles to
advance cancer CER.
We present recommendations corresponding to the major themes identified in this study,
with a goal of informing the evolution of the CER data framework, resolving data gaps, and
ultimately establishing a national data infrastructure for cancer CER. Our focus was on
existing secondary, observational data, though findings we present are also applicable to
prospective data collection and future data resources.
1. There is a need for systematically identified, standardized measures to fill data gaps and
enhance linkages and transferability
Inconsistent, incomplete measures and a lack of data standardization pose a substantial
threat to improving public health through CER. Stakeholders (e.g., researchers, providers,
payers) collect clinical, population, and health services data in numerous ways. Even within
the research community, there are substantial differences of opinion on essential variables.
This lack of consensus inhibits comparability across and within health datasets.
Recommendation 1a: Systematically identify necessary measures including
uniform definitions and standardization of collection and coding—Intervention
selection, exposure assignment, and outcome measures must be systematically identified and
characterized. As a starting point, the study authors have recommended a framework for
identifying measures across the cancer care continuum.9 Standards for how measures are
defined, collected, and coded must be developed and broadly applied, even for very basic
measures such as race and ethnicity. This issue extends to algorithms for defining
meaningful measures and cohorts, or deriving complex treatments or outcomes. Lack of
global standardization inhibits data pooling, comparability among multiple sources, and
generalizability of findings in the context of population heterogeneity.30
A multidisciplinary panel of CER researchers, stakeholders, and their partners is required to
address this diversity of measures and lack of data standardization. A goal of such an effort
should be identification of a minimum basic set of essential measures in all new data
collection initiatives, including standardized data definitions.
Recommendation 1b: Develop and incorporate new measures and dataset
crosswalks to address gaps among current data resources—Additional
measures must be identified which incorporate advances in medicine and health sciences. A
key example is the enhancement of our national cancer registries’ collection of data on
genetic markers. These tests, like the KRAS test, are increasingly able to provide predictive
insight into intervention effectiveness for individual patients.31-33 Because of the potentially
rapid and inconsistent adoption of these markers, multi-concept coding systems are
necessary to capture (1) if the test was used, (2) test results, and (3) test characteristics. In
addition genetic markers, federal and other payers could consider standardization of clinical
markers such as stage, grade, and performance status. The current utilization of ICD-9 and
Healthcare Common Procedural Coding System (HCPCS) codes is insufficient in this
cancer-specific context. Furthermore, investment in measurement and methods research
could facilitate the development of ‘crosswalks’ between existing measures and
instruments.34, 35 This will enable the comparison of constructs between datasets and offer
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potential mechanisms for combining existing data, or supplementing missing
information.36, 37
Increasingly relevant for cancer CER are intermediate outcomes, including patient reported
outcomes.38-42 Historically, clinical research has focused on mortality, but through advances
in cancer detection and treatment, patients are living longer and may not die from cancer. To
enable better comparisons between treatments new measures are needed which go beyond
life expectancy and better quantify side-effects, costs, and other trade-offs such as the
probability of continuing to work or attending to family needs.43, 44 Patient treatment
decisions are increasingly likely to be informed by factors such as these. Systems to capture
these measures must be better integrated into clinical care data, and embedded in future
datasets.30
Recommendation 1c: Establish data architecture and systems standards for
collecting and communicating these measures among health care delivery
and financing organizations and researchers—To date, health care reform has
focused on standards for patient care, transferability (Health Information Exchange [HIE]),
and quality of care evaluations; however, CER also needs to be included as a priority
component for improving health care. “Meaningful use” regulations offer significant
incentives to standardize clinical data for transferability and interoperability, though these
efforts are still nascent. Accordingly, CER stakeholder involvement is critical in the
discussions between Centers for Medicare & Medicaid Services (CMS) and the Office of the
National Coordinator for Health Information Technology (ONC), and must extend beyond
meaningful use requirements for HIT development and requirements. NCI's cancer
Biomedical Informatics Grid (caBIG) and Cancer Data Standards Registry and Repository
(caDSR) have already developed an interoperable information technology (IT) infrastructure
that offers standard rules, unified architecture, and common language to develop and use
cancer research data.30 It is vital that open-source, open-access tools such as these remain at
the forefront of integrating with health care data coding such as Systematized Nomenclature
of Medicine – Clinical Terms (SNOMED CT), Logical Observation Identifiers Names and
Codes (LOINC), or data interoperability such as HL7.
2. Improvements in study design and population sampling are critical for CER studies to
be meaningful
Many of the problems with existing data sources cannot be solved through data
standardization or sophisticated statistical methods. For example, a greater quantity of data
will not necessarily make CER studies more generalizable or reproducible; rather, CER
study design issues need to be better understood and overcome, resulting in better quality
data.
While the focus of this work is not statistical methods or study design, data and study
methodology are inexorably connected. Recognizing this, future studies need to
prospectively apply more advanced data collection, better study designs, and sampling
frameworks. At the same time, investments need to be made in ways to reduce bias through
advanced statistical methods.33 By funding research on study design issues in existing CER
studies, we can develop better methods to apply toward future studies and data collection. It
is also important to recognize that the advancement of complex methods requires
consistency of measures and data interoperability described in the first recommendation.
Recommendation 2a: Develop methods to leverage existing data, overcome
data limitations, and reduce bias—The majority of data currently used for CER is
collected for non-research purposes and is non-experimental with regard to most CER
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questions. Consequently, several significant sources of bias exist, some of which are
correctable through advanced methods. Other sources of error are quantifiable, but cannot be
adequately addressed. The development and application of better analytic methods can help
overcome the design limitations of existing data. Propensity score matching and
instrumental variable analysis are two important examples of statistical approaches that can
capitalize on important data elements and advanced methods.
Many biases or data uncertainties can also be examined using specifically collected data or
hybrid data sources. For example, linking administrative data to epidemiologic or clinical
data (e.g., SEER-Medicare linked data45) creates powerful research resources that serve as
models for other such efforts.46 Other approaches include ancillary or validation studies
collecting new data on a subgroup of the main population, or an external population, to
supplement missing information or to extrapolate the distribution of an important variable
into the study population.47-50
Recommendation 2b: Facilitate the conduct and completion of pragmatic
trials for CER—Pragmatic trials can overcome many limitations of randomized clinical
trials (namely, limited sample sizes and restrictive inclusion criteria). Pragmatic trials
employ randomization but aim to make eligibility criteria and treatment decisions
representative of “real world” settings.4 They also collect information on a broader number
of risks, determinants, health outcomes, and events, either directly or through the novel and
efficient use of other data sources (e.g., claims/administrative data). As such, they can yield
more generalizable findings. In addition to these benefits, increased funding for pragmatic
trials could also help spur methods development on sampling and design issues commonly
seen in traditional CER studies.51
3. Issues of data ownership, access, governance, and cost are substantial
There are many large data resources and innumerous small datasets relevant to cancer CER.
However, there are significant barriers limiting their use including political obstacles, costs,
and administrative burden associated with data access. 25 Important and timely data are
often closely controlled by those who collect the data. Even data from federally funded
studies may languish as the investigative team exhausts its “first right of publication.” The
potential benefits from additional data linkages are prevented by lack of access, cost, or
tightly constrained data use agreements. For example, developing resources analogous to
SEER-Medicare for the under-65 population is imminently feasible by linking registry data
to private payer data. However, efforts to do so have commonly met with reluctance on the
part of the payers and even registries. For these groups, research is not a primary priority,
and the risks or “unknowns” are perceived to outweigh the prospective benefits.
Recommendation 3: Develop systems to facilitate timely data sharing for
research supporting the public good—There are practical solutions to identify CER-
relevant datasets and facilitate their acquisition.52 This includes development of codified
relationships among federal agencies, their contractors, and many data-holders.25 For
example, the individual SEER or NPCR registries could approve a single data acquisition
process to be followed for all federally-contracted CER studies, which may relieve
administrative burden. The National Cancer Institute's Central Institutional Review Board
(IRB) may serve as a useful analog, as it was designed to relieve the work of the multitude
of institutional IRBs.53 However, it provides a cautionary tale, as the centralized IRB has
been criticized for replacing rather than relieving the work needed to open a study.54 Other
examples include the broad DUAs between Medicare and important epidemiologic cohorts
such as the Women's Health Initiative (WHI) study. Similar agreements could be developed
for important cancer studies, making them more accessible to the research community.
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Standardized relationships between state and federal agencies would help data-holders be
reassured that their data will be used appropriately, while distilling data acquisition logistics
to a formulaic process. These relationships would also help facilitate the timeliness of data
for research and enable quick turn-around on important questions. Regarding access to
costly or proprietary datasets, government stakeholders (e.g., AHRQ, NCI) may consider
directly lending their weight to developing special agreements for select restricted or tightly-
held datasets.
There may be utility in centrally-brokered and managed data subscriptions based on
standing data use agreements. For example, states such as Maine and Oregon have
implemented requirements that payers deposit “shadow claims” to public health agencies for
purposes of quality improvement and informing policy decisions.55 Formal mechanisms
could be established to facilitate the updating and regular access to such data for CER.
4. Data security, privacy, and confidentiality remain paramount
While access to data must be improved, data security, privacy, and confidentiality are
critical, and remain top concerns.56 Moreover, there are multiple laws and regulations
governing the maintenance, release, and use of many datasets, such as Medicare or Medicaid
claims.
Recommendation 4: Develop systems to assure data security, privacy, and
confidentiality with any enhanced access to data for CER—Two short-term
practical opportunities warrant further exploration. First, at the state-level, health
information exchange (HIE) is focusing on standardization of electronic health records and
rules governing data transfer and use. It is prudent that the federal CER agenda be
represented as new processes and regulations continue to be defined.57-60 Second,
developing a CER data security and utilization “accreditation” system may help assure
compliance with regulations. This would ensure a baseline level of IT sophistication that
facilitates data use while assuring data vendors that accredited research sites are top-tier,
“safe” data custodians. Examining the Centers for Medicare and Medicaid (CMS)
requirements of their quality improvement organizations (QIOs) 61 may be a first step to
developing such accreditation systems.
5. Broad multidisciplinary representation is necessary to effectively address these CER
data needs
The recommendations (from methods to policy) presented by this study's discussants are a
microcosm of the larger CER discussion and highlight many differences in the cultures,
values, terminology, measures, approaches, and priorities relevant for cancer CER, and are a
microcosm of the larger CER discussion.
Recommendation 5a: A collaborative, multidisciplinary approach must be
emphasized to successfully address data needs for CER—Multidisciplinary
representation is necessary to adequately capture important differences in the cultures,
values, and terminology surrounding perceptions of cancer CER and data issues.26
Accordingly, a critical step will be identifying individuals who can represent their
disciplines (and industries) to optimally advance the cancer CER discussion. To be
successful, these individuals must not only be technical experts, they must also be mavens
and translators who can bridge technical and disciplinary gaps to identify and achieve
solutions.62 Supporting the identification and ongoing communication of such a group will
be important to drive CER data needs forward.
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Recommendation 5b: CER stakeholders must be engaged and coordinated in
the development of rules and standards to inform health reform—Beyond
informing cancer CER and its data needs, it is important that a multidisciplinary advisory
group be well represented in the context of health care policy reform. It will be vital to
engage these diverse groups and address these issues in a timely and consistent manner – the
recently established Patient Centered Outcomes Research Institute (PCORI) is the obvious
choice to lead such an effort.63 PCORI can identify members of the research community and
partner with federal agencies. Both groups represent research need and interests and help
define the future of CER in the context of health reform. Additionally, PCORI is well
positioned to address other needs, such as maintaining a cancer CER data inventory, and
perhaps similar registries for protocols including those with null results. The Registry of
Patient Registries project is a promising project to begin to address this need.64, 65
Conclusions
By leveraging secondary data we can fill gaps and provide timely, valid, scientific
knowledge to systematically conduct CER and improve cancer care and outcomes.
However, substantial engagement is required from many organizations in order to address
the issues outlined here. Multidisciplinary individuals within these organizations need to be
identified who can help facilitate solutions in order for CER to reach its full potential.
The data ontology and recommendations we present provide guidance for critical
discussions between multidisciplinary teams of cancer researchers, methods experts, and
other stakeholders. They align with previous calls for infrastructure development to support
cancer research and CER.13, 15 Together they provide a template for systematically
addressing cancer CER data needs. By understanding and overcoming weaknesses in current
data, we can accelerate the pace of cancer CER, and ultimately enhance the adoption of CER
findings to improve patient-centered care and outcomes.
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Table 1
Data ontology and definitions.
Existing and Fixed data Definition
Experimental studies data Primary data collected for the purpose of studying the safety and efficacy of health and medical
interventions. Significant variation exists between types of studies with regards to utility for CER. For
example, phase III-IV randomized trials are more limited for CER versus pragmatic trials or large
epidemiologic trials (e.g., WHS, WHI, PHS).
Non-experimental studies data Data collected by public health researchers to identify patterns and determinants of diseases and outcomes
within a population (e.g., NHS, HPFS, ARIC).
Registry data Data collected by public health or other clinical health institutions to evaluate disease incidence, morbidity,
and outcomes for a population defined by a specific condition or exposure, including interventions (e.g.,
SEER)
Administrative / claims data Data collected for the business or programmatic purposes of documenting, delivering, or paying for health
care, including insurance companies, health systems, or government entities. May be for the purpose of
organizing, tracking and defining patient health and interactions with the healthcare system (e.g., Medicare,
Medicaid, MarketScan).
Electronic Health Records Data collected at point of care to support clinical care delivery, management, and decision making. These
data are stored/managed through specific computer-based software and information systems (e.g., HMO-
network).
Other data Various, yet untested for CER; examples include syndromic surveillance and or pharmacy purchase/market
data.
Hybrid data
Linked clinical and claims data Datasets created by the linkage between two unique data sources (often from the above categories) collected
by different entities and for different purposes (e.g., SEER-Medicare)
Validation study data Data collected or obtained for the purposes of overcoming limitations from existing/secondary data sources
(e.g., MCBS, POC)
Abbreviations: WHS: Women's Health Study; PHS: Physicians’ Health Study; NHS: Nurses Health Study; HPFS: Health Professionals Follow-up
Study; ARIC: Atherosclerosis Risk in Communities Study; MCBS: Medicare Current Beneficiary Survey; POC: Patterns of Care Study; etc.
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Table 2
Existing and secondary data sources: Illustrative examples, strengths, limitations and applicability/utility to
CER.
Examples Strengths Limitations Applicability/Utility to Cancer
CER
Existing and Fixed Data Sources






■ Women's Health Study
(WHS)
■ Detailed and unbiased
information on treatment, and
important clinical covariates
■ Enormous breadth and
diversity of data (across 12 NCI
cooperative groups)
■Limited generalizability
■ Expensive to conduct, requires
lengthy follow-up for many
outcomes
■ Limited sample sizes
■ Highly specific (i.e. usually
single treatment/intervention)
■ Limited in essential/important
covariates
■Utility for CER depends on type of
experimental study
■ Broadly defined (or population-
based) trials can be useful for CER;
but require extensive inclusion of
covariates outside of the main trial
aims
■ Secondary use of experimental
studies for CER could be improved
through investments in 1) Pragmatic
clinical trials and 2) methods /
design development













■Extensive data on diagnosis,
procedures and outcomes
■ Rich in covariates (risk
factors, important confounders)
■ Often include patient medical
records
■ Can be population-based
■Expensive to develop and
maintain
■ Logistics of study development
limit data availability and addition
of new hypotheses
■ Several biases may exist:
selection; information; recall; and
response
■ Unclear event temporality
between data collection waves
■ Limited in scope, statistical
power beyond initial study aims
■ Proprietary data requiring
extensive protocols, procedures
■ Can be leveraged for comparative
effectiveness depending on data
quality and extent of biases
■ Utility for CER also dependent on
study design, quality/completeness
of measures and broad inclusion
covariates
■ Can be strengthened through
potential data linkages to claims or
EHR data which can augment or off-
set biases/limitations (can provide






■ National Program of
Cancer Registries (NPCR)






■ Clinical information at point
of care or diagnosis
■ Simultaneously collected with
diagnosis and treatment
■ Opportunity for recruitment
into cohorts or trials





■ Primarily limited to first
occurrence of event or disease and
limited inclusion of covariates
■ Unknown response, toxicity,
patient reported outcomes
■ Challenging for longitudinal
data capture
■ Sparse patient identifiers
■ Challenging for selecting
controls / comparator populations
■Do not provide enough complete
data for rigorous CER
■ Linkages to additional data are
necessary to provide missing
information
■ Dearth of literature on solutions/
methods for inherent biases,
interoperable study design, and
evaluation/application of comparator
populations
4) Administrative and claims data
■Most health insurance
programs: Medicare;
Medicaid; Blue Cross /
Blue Shield, etc.
■ Medstat / Marketscan
■ United Health
■Represents large proportion of
US population
■ Rich patient-level data:
demographics, procedures,
treatments
■ Includes temporality of
events
■ Some include organizational/
provider characteristics
■ Most have unique identifiers
enabling linkage to other data
■Design/structure often impacts
data sensitivity/specificity
■ Missing important clinical
etiologic information
■ Includes date or type of testing
procedures, but no results (e.g.,
pathology, tumor response,
genetics, vital stats, etc.)
■ High patient turn-over
■ Complicated data structure
requires significant learning-curve
and programming resources
■ Burdensome and prohibitive
data use agreements
■ Expensive to obtain
■Missing key CER components
including vital tumor and disease
information
■ Linkages can supplement missing
information – but costs and/or
DUA's often inhibit additional
linkages
■ Utility for CER would be greatly
improved through institutional and
governmental policies which
overcome limitations (i.e., funding,
training, collaboration)
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Examples Strengths Limitations Applicability/Utility to Cancer
CER
■ Untimely data releases –
significant time lags





















■Allows for studies of toxicity,
quality of life, natural history
■Populations are not generalizable
■Lack of standardization of patient
information and clinical measures
between systems (technology, data
structure, and coding)
■Missing or insufficient data
elements necessary for CER
■Imperfect record keeping/follow
up - Patients not consistently
maintained within a single system/
EHR
■Enormous expense to obtain data
from private sector/vendors
■Currently there is limited utility for
EHR data from private vendors
■However examples from VA and
universal/national systems (UK,
Canada), exemplify potential of EHR
sources
■Future utility dependent on:
standardization of measures and data
systems/interoperability; standard
linkage variables; public and private















■Data at both patient and
ecological level
■Information on behavioral and
environmental risks




■ Unclear how to identify, define
and utilize these data
■ Utility to CER dependent on
integration into other data,
specifically clinical care data
Hybrid Data Sources
7) Linked clinical and claims data
■SEER-Medicare
■State Cancer Registry –
Medicare/Medicaid
■WHI-Medicare
■Includes clinical and health
services data
■Provides temporality of events
■Large population samples;
ability to study rare events/
treatments
■Provides access to controls or
comparison populations
■Allows for adjudication/
validation of events (i.e., self-
reported)
■Can detecting recurrence
■Missing information (eg, HMO
or supplemental insurance); often
highly specific populations (>65,
disabled, etc)
■Non-covered services are
excluded (e.g., prescription drugs,
long-term care, free screenings)
■Missing vital clinical information
(tumor response)




■Large, complex data require
advanced training/experience
■Delay in research access
■Powerful for CER studies because
of large, generalizable populations
■Large number of covariates and
clinical information
■Lengthy follow-up available
including information on temporality
of treatment and events
■Could be strengthened by linkages
to laboratory and clinical results






■Used to minimize limitations
of other data
■Can give estimates of
associations not discernable
within data
■Lack of validated studies exist
for CER
■Methodologic limitations and
lack of model transportability to
CER
■To be useful for CER an
investment in methodologic work is
required -- similar to P01 CA
142538 “Statistical Methods for
■ Cancer Clinical Trials” (PI,
Kosorok)
■Validation studies could lead to
immediate return of investment with
regard to leveraging existing data for
CER
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